Advances in therapeutic treatment options for ANCA-associated vasculitis

References

• Jennette JC, Falk RJ, Bacon AP, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatism. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, van Paassen P, Cohen Tervaert JW. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 2015;26(10):2314–2327.
   PubMed Web of Science ®Google Scholar
• Yates M, Watts AR, Bajema IM, et al. EULAR/ERAEDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76–85.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: A 30-year follow-up study. Nephrol Dialysis Transplantation. 2012;28(2):373–379.
   PubMed Web of Science ®Google Scholar
• Tuin J, Stassen PM, Bogdan DI, et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody–associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol. 2019;14(7):1021–1028.
   PubMed Web of Science ®Google Scholar
• McGeoch L, Twilt M, Famorca L, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43(1):97–120.
   PubMed Web of Science ®Google Scholar
• Chanouzas D, Anne J, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: A multicenter retrospective cohort study. BMC Nephrol. 2019;20(1):58.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: A systematic literature review. Clin Ther. 2011;33(10):1413–1432.
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14(1):73.
   PubMedGoogle Scholar
• Walsh M, Merkel PA, Peh C, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–631.
   PubMed Web of Science ®Google Scholar
• Furuta S, Sugiyama T, Umibe T, et al. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multi-centre, open-label, randomised controlled trial. BMJ Open. 2017;7(12):e018748.
   PubMed Web of Science ®Google Scholar
• Ma Y, Han F, Chen L, et al. The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: A retrospective study. BMC Nephrol. 2017;18(1):381.
   PubMedGoogle Scholar
• Miloslavsky EM, Niles JL, Wallace ZS, et al. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. Semin Arthritis Rheum. 2018;48(2):288–292.
   PubMed Web of Science ®Google Scholar
• Pepper RJ, McAdoo SP, Moran SM, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis. Rheumatology. 2019;58(2):260–268.
   PubMed Web of Science ®Google Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: A randomized. Ann Intern Med. 2009;150(10):670–680.
   PubMed Web of Science ®Google Scholar
• Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–960.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quéméneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients aged Sixty‐Five years or older: results of a multicenter, Open‐Label, randomized controlled trial of corticosteroid and Cyclophosphamide–Based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–1127.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220.
   PubMed Web of Science ®Google Scholar
• Jones RB, Furuta S, Cohen Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182.
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatism. 2013;65(9):2441–2449.
   PubMedGoogle Scholar
• Unizony S, Villarreal M, Miloslavsky EM, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166–1169.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Muhsin SA, Pendergraft III WF, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep. 2018;3(2):394–402.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Fragoulis GE, Venetsanopoulou A, et al. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2017;35(Suppl 103):155.
   PubMedGoogle Scholar
• McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dialysis Transplantation. 2018;34(1):63–73.
   Web of Science ®Google Scholar
• Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PloS One. 2012;7:5.
   Web of Science ®Google Scholar
• Huugen D, Van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71(7):646–654.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20(2):289–298.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Wiech T, Rudnick RB, et al. Complement inhibitors in clinical trials for glomerular diseases. Front Immunol. 2019;10:2166.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767.
   PubMed Web of Science ®Google Scholar
• Wetzels JFM, Sluiter HE, Hoitsma AJ, et al. Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988;33(6):1169–1174.
   PubMed Web of Science ®Google Scholar
• Reichert LJ, Koene RA, Wetzels JF. Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Nephrol Dialysis Transplant. 1999;14(1):91–97.
   PubMed Web of Science ®Google Scholar
• [Internet]. National Institute of health: U.S National library of medicine;A phase 3 clinical trial of CCX168 (Avacopan) in patients with ANCA-associated vasculitis (ADVOCATE);2016 [cited 2020 Apr]. Available from: https://clinicaltrials.gov/ct2/show/NCT02994927
   Google Scholar
• Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399–405.
   PubMed Web of Science ®Google Scholar
• Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis. 2007;66(6):798–802.
   PubMed Web of Science ®Google Scholar
• Kemna MJ, van Paassen P, Damoiseaux JG, et al. Maintaining remission in patients with granulomatosis with polyangiitis or microscopic polyangiitis: the role of ANCA. Expert Opin Orphan Drugs. 2017;5(3):207–218.
   Web of Science ®Google Scholar
• Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J.Am.Soc.Nephrol. 2007;18(7):2180–2188.
   PubMed Web of Science ®Google Scholar
• de Joode AA, Sanders JS, Smid WM, et al. Plasmapheresis rescue therapy in progressive systemic ANCA‐associated vasculitis: single‐center results of stepwise escalation of immunosuppression. J Clin Apheresis. 2014;29(5):266–272.
   PubMed Web of Science ®Google Scholar
• Derebail VK, Falk RJ. ANCA-associated vasculitis — refining therapy with plasma exchange and glucocorticoids. N Engl J Med. 2020;382(7):671–673.
   PubMed Web of Science ®Google Scholar
• Jayne D, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA‐associated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433–439.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology. 2020;59(5):959-9670.
   Google Scholar
• Cohen Tervaert JW. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. Curr Opin Rheumatol. 2018;30(4):388–394.
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 2005;52(8):2461–2469.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Westman K, Rasmussen N, et al. Brief report: long‐term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatism. 2012;64(10):3472–3477.
   PubMedGoogle Scholar
• Rodrigues JC, Collister D, Archer A, et al.The steroid tapering in ANCA vasculitis evaluation study (STAVE) 2: a systematic review and meta-analysis. Rheumatology. 2017;56(suppl 3):iii103.
   Google Scholar
• [Internet]. National institute of health: U.S national library of medicine;the assessment of prednisone in remission trial (TAPIR) - patient centric approach (TAPIR);2013 [cited 2020 Apr]. Available from: https://clinicaltrials.gov/ct2/show/NCT01933724
   Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–2803.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Pagnoux C, Perrodeau É, et al. Long-term outcomes among participants in the WEGENT trial of remission maintenance therapy for granulomatosis with polyangiitis (wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68(3):690–701.
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic Antibody–Associated vasculitis: A randomized controlled trial. JAMA. 2010;304(21):2381–2388.
   PubMed Web of Science ®Google Scholar
• Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in wegener’s granulomatosis. Rheumatology. 2004;43(3):315–320.
   PubMed Web of Science ®Google Scholar
• Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dialysis Transplant. 1998;13(8):2074–2076.
   PubMed Web of Science ®Google Scholar
• Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (wegener’s): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93(2):93.
   Web of Science ®Google Scholar
• Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662–1668.
   PubMed Web of Science ®Google Scholar
• Sanders JSF, de Joode AAE, DeSevaux RG, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: A randomized clinical trial. Nephrol Dialysis Transplantation. 2016;31(9):1453–1459.
   PubMed Web of Science ®Google Scholar
• Slot MC, Cohen Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C‐ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3–related vasculitis. Arthritis Care Res (Hoboken). 2004;51(2):269–273.
   Web of Science ®Google Scholar
• de Joode A, Stephan J, Puéchal X, et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term followup data. Rheumatology. 2017;56(11):1894–1901.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (wegener’s): ten-year experience at a single center. Arthritis Rheumatism. 2012;64(11):3770–3778.
   PubMedGoogle Scholar
• Smith RM, Jones RB, Guerry M, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatism. 2012;64(11):3760–3769.
   PubMedGoogle Scholar
• Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394–1400.
   PubMed Web of Science ®Google Scholar
• Pendergraft WF, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9(4):736–744.
   PubMed Web of Science ®Google Scholar
• Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology. 2013;52(11):2041–2047.
   PubMed Web of Science ®Google Scholar
• Calich AL, Puéchal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (wegener’s). results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135–141.
   PubMed Web of Science ®Google Scholar
• Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology. 2015;54(7):1153–1160.
   PubMed Web of Science ®Google Scholar
• Raffray L, Guillevin L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther. 2020 Apr 15 In press.
   PubMedGoogle Scholar
• Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143–1149.
   PubMed Web of Science ®Google Scholar
• [Internet]. National institute of health: U.S national library of medicine;comparison between a long term and a conventional maintenance treatment with rituximab (MAINRITSAN3);2015 [cited 2020 Apr]. Available from: https://clinicaltrials.gov/ct2/show/NCT02433522
   Google Scholar
• Smith R, Jayne D, Merkel P. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease. Arthritis Rheumatol. 2019;71(suppl_10); 1384.
   Google Scholar
• Stegeman CA, Cohen Tervaert JW, de Jong PE, et al. Trimethoprim–sulfamethoxazole (co-trimoxazole) for the prevention of relapses of wegener’s granulomatosis. N Engl J Med. 1996;335(1):16–20.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Wolter NE. Vasculitis of the upper airways. Swiss Med Wkly. 2012;142(1112):w 13541.
   PubMedGoogle Scholar
• Sachanandani NS, Piccirillo JF, Kramper MA, et al. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. Arch Otolaryngol. 2009;135(3):303–307.
   Google Scholar
• Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2015;26(3):537–542.
   PubMed Web of Science ®Google Scholar
• Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68(7):1700–1710.
   PubMed Web of Science ®Google Scholar
• Osman MS, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a “Personalized medicine approach” in ANCA-associated vasculitis. Curr Rheumatol Rep. 2019;21(12):1–7.
   PubMed Web of Science ®Google Scholar
• Kemna MJ, Plomp R, van Paassen P, et al. Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis. EBioMedicine. 2017;17:108–118.
   PubMed Web of Science ®Google Scholar
• Kemna MJ, Schlumberger W, van Paassen P, et al. The avidity of PR3‐ANCA in patients with granulomatosis with polyangiitis during follow‐up. Clin Exp Immunol. 2016;185(2):141–147.
   PubMed Web of Science ®Google Scholar
• Kemna MJ, Cohen Tervaert JW, Broen K, et al. Seasonal influence on the risk of relapse at a rise of antineutrophil cytoplasmic antibodies in vasculitis patients with renal involvement. J Rheumatol. 2017;44(4):473–481.
   PubMed Web of Science ®Google Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss)(EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–553.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis. 2016;75(2):396–401.
   PubMed Web of Science ®Google Scholar
• Kent BD, d’Ancona G, Fernandes M, et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020;6:1.
   Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Puéchal X. Targeted immunotherapy strategies in ANCA-associated vasculitis. Joint Bone Spine. 2019;86(3):321–326.
   PubMed Web of Science ®Google Scholar
• [Internet]. National institute of health: U.S national library of medicine;a study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) (MANDARA);2019 [cited 2020 Feb]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04157348
   Google Scholar
• Sozener ZC, Gorgulu B, Mungan D, et al. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. World Allergy Organ J. 2018;11(1):39.
   PubMedGoogle Scholar
• O’Malley L, Druce K, Chanouzas D, et al. The longitudinal course of fatigue in antineutrophil cytoplasmic antibody- associated vasculitis. J Rheumatol. 2020;47(4):572–579.
   PubMed Web of Science ®Google Scholar